NCT00822887 - Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

January 31, 2011

Conditions

Malignant Gliomas

Interventions

DRUG

Vandetanib

Dose level 1:100 mg qd Dose level 2:200 mg qd Dose level 3:300 mg qd

RADIATION

Fractionated Stereotactic Radiotherapy

All patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.

Trial Locations (1)

University of Colorado Health Science Center, Aurora